Drug Overview

Onfi (clobazam) is a specialized pharmacological intervention within the field of Neurology, specifically engineered for the management of severe, treatment-resistant seizure disorders. As a distinguished member of the benzodiazepine class, it is frequently utilized as a potent Targeted Therapy to stabilize neuronal activity in patients who have not achieved adequate seizure control with primary antiepileptic drugs.

Unlike traditional 1,4-benzodiazepines, Onfi is a 1,5-benzodiazepine, a structural distinction that often results in a more favorable side-effect profile, particularly regarding sedation. This “Smart Drug” approach allows for effective long-term seizure suppression while prioritizing the patient’s functional quality of life.

Generic Name: Clobazam
US Brand Names: Onfi, Sympazan (Oral Film)
Drug Category: Neurology / Anticonvulsant
Drug Class: 1,5-Benzodiazepine
Route of Administration: Oral (Tablet, Oral Suspension, or Oral Soluble Film)
FDA Approval Status: FDA-approved for adjunctive treatment of seizures associated with Lennox-Gastaut Syndrome.

Explore Onfi (clobazam) for Lennox-Gastaut syndrome and as an additional treatment in refractory epilepsies. Review our comprehensive medical protocols.

What Is It and How Does It Work? (Mechanism of Action)

The therapeutic efficacy of Onfi is rooted in its ability to enhance inhibitory neurotransmission within the Central Nervous System (CNS). At the molecular level, Onfi targets the \gamma-aminobutyric acid type A (GABA_A) receptor complex, which is the primary inhibitory rheostat of the brain.

Allosteric Modulation: Onfi binds to a specific site on the GABA_A receptor, distinct from the binding site of the neurotransmitter GABA itself. This binding is “allosteric,” meaning it changes the shape of the receptor to increase its affinity for GABA.
Chloride Channel Conductance: When GABA binds to its receptor in the presence of clobazam, the frequency of the integral chloride channel opening increases. This allows an influx of negatively charged chloride ions into the post-synaptic neuron.
Hyperpolarization: The influx of chloride ions increases the negative electrical charge inside the neuron (hyperpolarization), moving the membrane potential further away from the threshold required to trigger an action potential.
Seizure Threshold Elevation: By making it significantly harder for neurons to “fire,” Onfi effectively dampens the rapid, repetitive electrical discharges that characterize a seizure, thereby raising the overall seizure threshold.

FDA-Approved Clinical Indications

Primary Indication

Lennox–Gastaut Syndrome (LGS): Onfi is indicated for the adjunctive (add-on) treatment of seizures associated with Lennox-Gastaut Syndrome in patients 2 years of age and older.

Other Approved Uses

Refractory Epilepsies: While its primary label is for LGS, it is widely utilized in clinical neurology as an additional treatment for various forms of treatment-resistant focal and generalized epilepsies.
Catamenial Epilepsy: Occasionally used off-label for cyclical seizure exacerbations.

Dosage and Administration Protocols

Dosage is strictly weight-based and follows a tiered titration schedule to minimize the risk of somnolence and maximize tolerability.

Patient Weight	Starting Dose	Titration (Day 7)	Maintenance (Day 14)
≤ 30 kg	5 mg daily	5 mg twice daily	10 mg twice daily
> 30 kg	5 mg twice daily	10 mg twice daily	20 mg twice daily

Dose Adjustments and Specific Patient Populations:

Geriatric Patients: Start at the lowest dose and escalate slowly; elderly patients are more sensitive to CNS depression.
Hepatic Impairment: Clobazam is extensively metabolized by the liver (primarily via CYP2C19). Patients with mild-to-moderate hepatic impairment require a slower titration and lower target doses.
CYP2C19 Poor Metabolizers: These individuals may have higher concentrations of the active metabolite (N-desmethylclobazam). A dose reduction is generally required.

Clinical Efficacy and Research Results

Clinical data through 2026 confirms that Onfi remains a high-performance choice for complex epilepsy syndromes.

Numerical data highlights:

Seizure Reduction (CONTAIN Trial): In pivotal clinical trials, patients on high-dose clobazam experienced a median reduction in the frequency of drop seizures (atonic seizures) of approximately 65-68% compared to baseline.
Responder Rate: Approximately 75% of patients treated with the maintenance dose achieved at least a 50% reduction in total seizure frequency.
Sustained Efficacy: Long-term follow-up research (2024-2025) indicates that, unlike some other benzodiazepines, the “honeymoon effect” (tolerance) is less pronounced with Onfi, with over 60% of responders maintaining efficacy for more than two years.

Safety Profile and Side Effects

Black Box Warning

WARNING: RISKS FROM CONCOMITANT USE WITH OPIOIDS. Concomitant use of benzodiazepines and opioids may result in profound sedation, respiratory depression, coma, and death. Reserve concomitant prescribing of these drugs for use in patients for whom alternative treatment options are inadequate.

Common Side Effects (>10%)

Somnolence (Drowsiness) and Sedation: The most frequently reported adverse effect.
Pyrexia (Fever): Observed particularly in pediatric populations.
Lethargy and Drooling: Especially in younger children or those on multiple antiepileptic drugs.

Serious Adverse Events

Serious Skin Reactions: Including Stevens-Johnson Syndrome (SJS) and Toxic Epidermal Necrolysis (TEN). These can occur at any time but are most common in the first 8 weeks.
Suicidal Ideation: As with all anticonvulsants, patients should be monitored for changes in mood or suicidal thoughts.
Withdrawal Symptoms: Abrupt discontinuation can lead to seizures, hallucinations, and tremors.

Management Strategies

Skin Monitoring: Discontinue Onfi at the first sign of a rash unless the rash is clearly not drug-related.
Gradual Taper: If the drug must be stopped, it should be tapered by decreasing the dose by 5–10 mg per week.

Research Areas

In the context of Regenerative Medicine, current Research Areas (2025-2026) are investigating the role of GABA_A modulation in promoting a permissive environment for Cellular Therapy. Early-stage clinical trials are exploring whether the stabilization of neural circuits with Onfi can improve the integration and “synaptic hooking” of transplanted inhibitory interneurons. By reducing excitotoxicity, Onfi may serve as a critical bridge in Tissue Repair protocols for patients undergoing experimental stem cell treatments for refractory focal epilepsy.

Patient Management and Practical Recommendations

Pre-treatment Tests

CYP2C19 Genotyping: Recommended for identifying patients who may require lower starting doses.
Baseline CBC and Liver Function Tests: To establish a metabolic baseline.

Precautions During Treatment

Respiratory Monitoring: Caution in patients with pre-existing respiratory disease (e.g., sleep apnea or COPD).
Activity Adjustment: Avoid driving or operating heavy machinery until the effects of the medication are fully understood.

“Do’s and Don’ts”

DO take the medication consistently. If using the tablet form, it can be taken whole, crushed, or mixed with applesauce.
DO report any new rash, fever, or swollen glands to your neurologist immediately.
DON’T consume alcohol while taking Onfi, as it significantly increases the risk of dangerous sedation.
DON’T stop the medication suddenly, as this may trigger status epilepticus (prolonged seizures).

Legal Disclaimer

The information provided in this guide is for informational purposes only and does not replace professional medical advice, diagnosis, or treatment. Always seek the advice of your physician or other qualified health provider with any questions you may have regarding a medical condition or the use of Onfi. This medication should only be used under the direct supervision of a licensed Neurologist.